Google plans to use artificial intelligence to detect eye diseases

Google is planning to teach a computer to detect certain kinds of eye diseases, including diabetic retinopathy and macular degeneration.

"Teach" is not just a tech buzzword used by Google. The company plans to use artificial intelligence to actually teach machines to detect patterns in the records of 1.6 million London patients, according to USA Today. It’ll access the patient records through an ongoing agreement with the U.K.’s National Health Service.

The plan is to diagnose the diseases earlier and more accurately than human doctors, whose own accuracy in that area is only between 10 and 20 percent, USA Today said. The machines will learn to detect the disease better by having access to such a large number of patient records. They will be able to analyze what one researcher involved in the project described as “10,000 lifetimes’” worth of data, instead of the only one lifetime’s worth of experience afforded to an individual physician.

Google’s offshoot called DeepMind will manage the operation, reviewing retina scans taken at London's Moorfields Eye Hospital between 2007 and 2016, Newsweek reported.

“There’s so much at stake, particularly with diabetic retinopathy,” DeepMind’s co-founder Mustafa Suleyman told the Guardian. "If you have diabetes, you’re 25 times more likely to go blind. If we can detect this, and get in there as early as possible, then 98 percent of the most severe visual loss might be prevented."

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.